Welcome to our dedicated page for Infusystem Hld SEC filings (Ticker: INFU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InfuSystem’s business might look straightforward—renting and servicing infusion pumps—but its SEC disclosures reveal a maze of reimbursement rules, device safety updates and segment revenue math. Finding the oncology pump utilisation rate or the margin on biomedical repairs inside a 300-page report can slow even seasoned analysts.
That’s why this page brings every InfuSystem SEC filing explained simply. Stock Titan’s AI surfaces key details within minutes, whether you need an InfuSystem annual report 10-K simplified or an InfuSystem quarterly earnings report 10-Q filing. Ask natural questions like “What does InfuSystem report about payer mix?” and our algorithms point you to the exact footnote. Real-time alerts ensure InfuSystem Form 4 insider transactions are flagged the moment executives trade.
Use the full range of documents without scrolling through EDGAR:
- Form 4: Track InfuSystem insider trading Form 4 transactions and receive InfuSystem Form 4 insider transactions real-time notifications.
- 10-Q: Get concise InfuSystem earnings report filing analysis with segment breakouts and cash-flow highlights.
- 10-K: Understand long-term pump fleet commitments via understanding InfuSystem SEC documents with AI.
- 8-K: See InfuSystem 8-K material events explained when new payer contracts or device recalls hit the wire.
- DEF 14A: Review the InfuSystem proxy statement executive compensation tables without digging through PDFs.
Whether you’re monitoring InfuSystem executive stock transactions Form 4 before contract renewals or benchmarking quarter-over-quarter repair revenue, Stock Titan delivers AI-powered summaries, expert context and continuous updates—so you can act with confidence instead of paging through documents.
InfuSystem Holdings (INFU) insider transaction: EVP-Chief HR Officer Jerod Funke reported RSU settlement on October 9, 2025. Restricted stock units converted into common stock on a one-for-one basis, resulting in 12,500 shares acquired at $0 per share via code “M”. To cover taxes, the issuer withheld 3,669 shares at $9.61 under code “F”.
After these transactions, Funke directly owned 18,662 shares of InfuSystem common stock.
Insider filing for Carrie Lachance, President and CEO of InfuSystem Holdings (INFU). On 09/23/2025, 50,000 performance-based restricted stock units granted May 16, 2025, vested and were settled into common stock. The issuer withheld 19,675 shares to cover tax withholding at an indicated value of $10.22 per share, leaving the reporting person with 232,174 shares beneficially owned after the transactions. The Form 4 shows the reporting person held 201,849 shares before the vesting, which increased to 251,849 upon settlement then decreased due to withholding. This filing documents routine equity compensation vesting and related tax withholding by an executive who is also a director.
InfuSystem Holdings insider Scott Shuda reported changes in beneficial ownership. Mr. Shuda, identified as a director, disclosed indirect ownership of 298,383 shares through entities Meridian and BlueLine. He recorded a distribution on 07/07/2025 that reduced holdings by 2,242 shares and a sale on 08/22/2025 of 5,752 shares at an average price of $9.67 (individual sale prices ranged $9.57–$9.83). Following the reported transactions, the filing shows 94,000 shares owned (direct or indirect) after the August sale. The Form 4 notes the sold shares originated from a dissolved partnership and no further sales are planned relating to that partnership.
InfuSystem Holdings, Inc. (INFU) filed a Form 144 notifying an intended open-market sale of 5,752 common shares through Charles Schwab with an aggregate market value of $56,455. The filing states the shares were originally acquired on 08/01/2017 via open-market purchase and payment in cash. The proposed approximate sale date is 08/22/2025, and the filing reports 20,425,964 shares outstanding for the issuer. No securities of the issuer were reported sold by the same person in the past three months. The filer affirms they are not aware of any undisclosed material adverse information.
AWM Investment Company, Inc. filed an amendment to Schedule 13G reporting beneficial ownership of 1,272,296 shares of InfuSystem Holdings, Inc. common stock, representing 6.1% of the outstanding class. AWM states it is the investment adviser to Special Situations Life Sciences Fund, L.P. (SSLS) and holds sole voting and sole dispositive power over the shares held by SSLS. The filing discloses Delaware organization for AWM, the issuer's principal office in Rochester Hills, Michigan, and confirms the stake was acquired and is held in the ordinary course of business, not for the purpose of changing control.
FAQ
What is the current stock price of Infusystem Hld (INFU)?
What is the market cap of Infusystem Hld (INFU)?
